| Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a … RS Herbst, HT Arkenau, R Santana-Davila, E Calvo, L Paz-Ares, ... The Lancet Oncology 20 (8), 1109-1123, 2019 | 232 | 2019 |
| Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open‐label, phase I trial (JVDF) HT Arkenau, J Martin‐Liberal, E Calvo, N Penel, MG Krebs, RS Herbst, ... The oncologist 23 (12), 1407-e136, 2018 | 141 | 2018 |
| Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open … YJ Bang, T Golan, L Dahan, S Fu, V Moreno, K Park, R Geva, F De Braud, ... European Journal of Cancer 137, 272-284, 2020 | 103 | 2020 |
| Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC RS Herbst, HT Arkenau, J Bendell, E Arrowsmith, M Wermke, A Soriano, ... Journal of Thoracic Oncology 16 (2), 289-298, 2021 | 39 | 2021 |
| Length Bias Correction in Gene Ontology Enrichment Analysis Using Logistic Regression G Mi, Y Di, S Emerson, JS Cumbie, JH Chang PLOS ONE 7 (10), e46128, 2012 | 37 | 2012 |
| A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung … RS Herbst, JC Bendell, N Isambert, E Calvo, R Santana-Davila, P Cassier, ... Journal of Clinical Oncology 34 (15_suppl), 3056-3056, 2016 | 33 | 2016 |
| Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a … YJ Bang, T Golan, CC Lin, YK Kang, ZA Wainberg, H Wasserstrom, J Jin, ... Journal of Clinical Oncology 36 (4_suppl), 92-92, 2018 | 32 | 2018 |
| Ramucirumab (Ram) and durvalumab (Durva) treatment of metastatic non-small cell lung cancer (NSCLC), gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, and … YJ Bang, T Golan, CC Lin, L Dahan, S Fu, V Moreno, R Geva, M Reck, ... Journal of Clinical Oncology 37 (15_suppl), 2528-2528, 2019 | 30 | 2019 |
| Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results … I Chau, N Penel, HT Arkenau, R Santana-Davila, E Calvo, AO Soriano, ... Journal of Clinical Oncology 36 (4_suppl), 101-101, 2018 | 28 | 2018 |
| A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts). S Pant, JC Bendell, RJ Sullivan, G Shapiro, M Millward, G Mi, E Yuen, ... Journal of Clinical Oncology 37 (15_suppl), 3001-3001, 2019 | 25 | 2019 |
| A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. DP Petrylak, HT Arkenau, JL Perez-Gracia, M Krebs, R Santana-Davila, ... Journal of Clinical Oncology 35 (6_suppl), 349-349, 2017 | 25 | 2017 |
| Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab … I Chau, JC Bendell, E Calvo, R Santana-Davila, J Rodon Ahnert, N Penel, ... Journal of Clinical Oncology 35 (4_suppl), 102-102, 2017 | 24 | 2017 |
| Ramucirumab in combination with pembrolizumab in treatment-naïve advanced gastric or GEJ adenocarcinoma: safety and antitumor activity from the phase 1a/b JVDF trial I Chau, N Penel, AO Soriano, HT Arkenau, J Cultrera, R Santana-Davila, ... Cancers 12 (10), 2985, 2020 | 23 | 2020 |
| Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I … I Chau, JC Bendell, E Calvo, R Santana-Davila, HT Arkenau, G Mi, J Jin, ... Journal of Clinical Oncology 35 (15_suppl), 4046-4046, 2017 | 23 | 2017 |
| Goodness-of-fit tests and model diagnostics for negative binomial regression of RNA sequencing data G Mi, Y Di, DW Schafer PLoS One 10 (3), e0119254, 2015 | 22 | 2015 |
| EGFR gene copy number by FISH may predict outcome of necitumumab in squamous lung carcinomas: analysis from the SQUIRE study C Genova, MA Socinski, RR Hozak, G Mi, R Kurek, J Shahidi, L Paz-Ares, ... Journal of Thoracic Oncology 13 (2), 228-236, 2018 | 18 | 2018 |
| Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P) RS Herbst, J Martin-Liberal, E Calvo, N Isambert, JC Bendell, P Cassier, ... Annals of Oncology 27, vi574, 2016 | 14 | 2016 |
| Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data RS Herbst, J Martin-Liberal, E Calvo, N Isambert, J Bendell, P Cassier, ... Annals of Oncology 28, ii32-ii33, 2017 | 12 | 2017 |
| Ramucirumab safety in East Asian patients: a meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials CJ Yen, K Muro, TW Kim, M Kudo, JY Shih, KW Lee, Y Chao, SW Kim, ... Journal of global oncology 4, 1-12, 2018 | 9 | 2018 |
| A multi-cohort phase 1 study of ramucirumab plus durvalumab: preliminary safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric … T Golan, CC Lin, S Fu, H Wasserstrom, G Mi, N Laing, M Karasarides, ... Annals of Oncology 28, iii5, 2017 | 8 | 2017 |
Roy S. Herbst, MD, PhDYale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New HavenVerified email at yale.edu
